Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating neovascularization

a neovascularization and ocular technology, applied in the field of improved methods for treating ocular neovascularization, can solve problems such as choroidal neovascularization recurren

Inactive Publication Date: 2006-11-23
NOVARTIS AG
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a method for treating unwanted neovasculature (the formation of new blood vessels) in a subject. The method involves administering an anti-angiogenic agent and a photosensitive agent to the subject, and then using light to irradiate the neovasculature. The invention also includes a kit containing both an anti-angiogenic agent and a photosensitive agent. The technical effect of this invention is to provide a more effective treatment for unwanted neovasculature.

Problems solved by technology

However, it has been demonstrated that in patients treated with PDT there can be a recurrence of choroidal neovascularization within the treatment area and / or development of new lesions outside the original lesions (so called progression) such that repeated PDT is required.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating neovascularization
  • Method for treating neovascularization

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009] It has now been found that administration of an anti-angiogenic can be used in conjunction with PDT for the treatment of a subject having unwanted ocular neovasculature, e.g. CNV.

[0010] PDT as a treatment is well known in the art, and generally involves the use of a photosensitive agent activated by a laser. Preferred methods and compositions for PDT treatment of neovascularization utilizing a photosensitive agent and laser treatment is disclosed in U.S. Pat. Nos. 4,920,143; 5,095,030; 5,214,036; 5,707,608; 6,074,666; 5,770,619; 5,798,349; 5,756,541; 4,883,790; and 5,283,255, all of which are expressly incorporated by reference herein in their entirety. When PDT is employed to treat ocular neovascularization, the photosensitive agent lodges in the ocular tissue affected by neovascularization (i.e., the target ocular tissue) and is activated by a laser having a wavelength absorbable by the photosensitive agent. In the present invention, an anti-angiogenic agent is administere...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
photosensitiveaaaaaaaaaa
wavelengthaaaaaaaaaa
body surface areaaaaaaaaaaa
Login to View More

Abstract

The present invention describes an improved photodynamic treatment to treat subfoveal choroidal neovascularization (CNV).

Description

[0001] This application claims priority under 35 U.S.C. § 119(e) from provisional patent application Ser. No. 60 / 191,807, filed Mar. 24, 2000, the entire disclosure of which is incorporated by reference herein in its entirety.FIELD OF THE INVENTION [0002] The invention relates to an improved method to treat ocular neovascularization, such as subfoveal choroidal neovascularization (CNV) by use of an anti-angiogenic agent as an adjunct to photodynamic therapy (PDT). BACKGROUND OF THE INVENTION [0003] The present treatment of age related macular degeneration (AMD) with photodynamic therapy using an appropriate photosensitive agent leads to excellent short-term results for treating CNV and is a significant improvement over laser photocoagulation. However, it has been demonstrated that in patients treated with PDT there can be a recurrence of choroidal neovascularization within the treatment area and / or development of new lesions outside the original lesions (so called progression) such ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/00A61K31/122A61K31/409A61K31/501A61K31/553A61K38/00A61K38/08A61K41/00A61K45/00A61K45/06A61P9/00A61P27/02A61P43/00
CPCA61K31/409A61K31/501A61K31/553A61K41/0057A61K45/06A61K41/0071A61K31/4025A61P27/00A61P27/02A61P35/00A61P43/00A61P9/00A61P9/14A61K41/00
Inventor BRAZZELL, ROMULUS
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com